Premium
Matrix metalloproteinases in inflammatory myopathies: enhanced immunoreactivity near atrophic myofibers
Author(s) -
Schoser B. G. H.,
Blottner D.,
Stuerenburg H.J.
Publication year - 2002
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1034/j.1600-0404.2002.1o104.x
Subject(s) - polymyositis , matrix metalloproteinase , dermatomyositis , immunocytochemistry , pathology , inflammation , atrophy , immunohistochemistry , biology , medicine , immunology
Objectives – To further examine the role of proteolytic enzyme expression of matrix metalloproteinases (MMP) and T‐cell markers in inflammatory myopathies and controls. Material and methods – We studied the expression of MMP‐2, MMP‐7, and MMP‐9 in 19 cases of inflammatory myopathies and controls using immunocytochemistry. Results – Inflammatory myopathies showed distinct patterns of up‐regulation of MMP. MMP‐9 was strongly expressed in atrophic myofibers in all inflammatory myopathies. MMP‐2 immunoreactivity was similar in its distribution, however, to a weaker intensity. In dermatomyositis the perifascicular atrophy showed pronounced MMP‐9 immunoreactivity, probably reflecting denervated patterns of myofibers. Moreover, MMP‐7 strongly immunolabeled invaded myofibers in polymyositis cases only. Conclusion – These patterns confirm, that MMP‐7 up‐regulation is prominent in PM, while MMP‐2 immunoreactivity is only slightly elevated in inflamed muscle. In general, MMP‐9 up‐regulation appears to be an important additional molecular event in the multistep process of all inflammatory myopathies.